John Cox, Dyne Therapeutics CEO
Dyne details pivotal plans for myotonic dystrophy RNA drug, though data blip worries some investors
Dyne Therapeutics touted an early-stage study of its RNA treatment for myotonic dystrophy type 1 and has selected the dose it plans to move forward …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
